Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Team Maps Epigenetic Changes in Stem Cells

August 17, 2010 6:16 am | News | Comments

Having charted the occurrence of a common chemical change that takes place while stem cells decide their fates and progress from precursor to progeny, a team of scientists has produced the first-ever epigenetic landscape map for tissue differentiation.

TOPICS:

New Targets Discovered For Anti-Angiogenesis Drugs

August 17, 2010 6:13 am | News | Comments

A new study describes how a carbohydrate-binding protein, galectin-3, promotes angiogenesis, the growth of new blood vessels. Targeting the protein, scientists identified two approaches that significantly reduced angiogenesis in mice.

TOPICS:

Pfizer Granted Approval For New XYNTHA Delivery Method

August 17, 2010 6:04 am | News | Comments

Pfizer Inc. announced that the U.S. Food and Drug Administration has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients.

TOPICS:
Advertisement

FDA Questions Expanded Cymbalta Use

August 17, 2010 5:52 am | by Matthew Perrone | News | Comments

Federal health scientists are questioning whether the antidepressant Cymbalta is safe and effective enough to be approved for use against chronic pain.

TOPICS:

Feds Push to Withdraw ProAmatine

August 17, 2010 5:50 am | by Matthew Perrone | News | Comments

Federal health regulators are pushing to withdraw a blood pressure drug that has been on the market for 14 years in spite of the manufacturer's failure to submit evidence that it actually helps patients.

TOPICS:

Berkshire Hathaway Ups Stake In J & J

August 17, 2010 5:47 am | by Josh Funk | News | Comments

Warren Buffett's Berkshire Hathaway Inc. has partially rebuilt the stake in Johnson & Johnson he reduced over the past two years to raise cash for other investments.

TOPICS:

Lilly Halts Disappointing Alzheimer's Treatment

August 17, 2010 5:43 am | News | Comments

Drugmaker Eli Lilly and Co. has stopped developing a potential Alzheimer's disease treatment in late-stage testing after patients taking the drug fared worse than those on a placebo.

TOPICS:

HDL Mimetic Targets Atherosclerosis

August 16, 2010 10:58 am | by Narendra Lalwani, PhD, Chief Scientific Officer, Cerenis Therapeutics, Inc, Ann Arbor, Mich. | News | Comments

CER-001 is an experimental high-density lipoproteins mimetic being developed by Cerenis Therapeutics. This class of drugs removes cholesterol from the vessel wall to treat high-risk atherosclerosis, including acute coronary syndrome.

TOPICS:
Advertisement

New Targets, Dual Agonists Increase Possibilities for Treating Diabetes

August 16, 2010 10:45 am | by Fritz French, Chief Executive Officer, Marcadia Biotech, Carmel, Ind. | News | Comments

In recent years, treatment strategies for type 2 diabetes have been focused on the development of novel therapeutic options, especially new drugs targeting the incretin system.

TOPICS:

UV-VIS Flash Purification

August 16, 2010 8:33 am | Product Releases | Comments

Biotage, a leading developer of tools and technology for medicinal and analytical chemistry, announces the introduction of the Isolera UV-VIS flash purification system.

TOPICS:

Phosphorylation Tool

August 16, 2010 8:30 am | Product Releases | Comments

Sage-N Research Inc., a leader in computational proteomics, announces the integration of the first commercially available phosphorylation tool using mass spectrometry into its drug discovery platform.

TOPICS:

New Method Predicts Nanointeractions

August 16, 2010 8:12 am | News | Comments

Researchers at North Carolina State University have developed a method for predicting the ways nanoparticles will interact with biological systems – including the human body.

TOPICS:

Leaders Advocate Expanded Cancer Care In Developing World

August 16, 2010 8:10 am | News | Comments

Once thought to be a problem primarily in the developed world, cancer is now a leading cause of death and disability in poorer countries. Almost two-thirds of the 7.6 million cancer deaths in the world occur in low- and middle-income countries.

TOPICS:

Medco Buys Clinical Trial Tech Maker

August 16, 2010 8:02 am | News | Comments

Pharmacy benefits manager Medco Health Solutions Inc. said it will buy United BioSource Corp., which develops technology used in clinical trials and patient monitoring, for $730 million in cash.

TOPICS:

Vectibix Disappoints in Phase 3 Trial

August 16, 2010 7:59 am | News | Comments

Amgen announced top-line results from a randomized Phase 3 trial evaluating Vectibix as a first-line treatment in patients with recurrent and/or metastatic squamous cell head and neck cancer.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading